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identiﬁed for study inclusion. Sildenaﬁl was the most common initial treatment (n = 
455 patients), followed by bosentan (n = 251 patients) and ambrisentan (n = 21 
patients). On average, ambrisentan patients received one pill/day with a daily dose of 
7 mg, bosentan patients received 2 pills/day with a daily dose of 222 mg, and sildenaﬁl 
patients received 2.3 pills/day with a daily dose of 61 mg. Approximately 44% of 
ambrisentan, 35% of bosentan, and 25% of sildenaﬁl patients experienced a dose 
increase (p = 0.013) during the follow-up period. PAH-related inpatient and emergency 
department utilization were similar among the groups, while ambulatory visits differed 
among the groups, with average monthly counts of 1.2, 0.8, and 0.5 visits for ambris-
entan, bosentan, and sildenaﬁl patients (p < 0.001). Follow-up total PAH-related costs 
were signiﬁcantly different among the groups, with average monthly costs of $6820, 
$5332, and $3632 for ambrisentan, bosentan, and sildenaﬁl patients (p = 0.020). Cost 
differences were primarily driven by PAH-related pharmacy costs, which were signiﬁ-
cantly lower in sildenaﬁl patients (p < 0.001). CONCLUSIONS: Of the three oral 
PAH treatments studied, sildenaﬁl was the most frequently prescribed, and was associ-
ated with lower pharmacy and overall costs than either ambrisentan or bosentan.
CARDIOVASCULAR DISORDERS – Conceptual Papers & Research  
on Methods
PCV153
FAILURE OF THE BLAND-ALTMAN METHOD TO IDENTIFY CLINICALLY 
IMPORTANT DISAGREEMENT BETWEEN MEASURES OF THE 
INTERNATIONAL NORMALIZED RATIO
Shermock KM
The Johns Hopkins Medical Institutions, Baltimore, MD, USA
OBJECTIVES: The Bland-Altman method is often upheld as the optimal method to 
assess agreement between alternate measures of the same clinical parameter. However, 
recent research by our group demonstrates the Bland-Altman method does not report 
agreement in a clinically meaningful way. The objective was to determine if the Bland-
Altman method distinguished between two point-of-care (POC) INR devices. These 
devices were previously shown to have signiﬁcantly different levels of agreement with 
our core laboratory. METHODS: In a previous experiment, 170 patients provided 
three separate INR measures at the same clinic visit—two by POC (AvosureTM and 
ProTimeTM devices) and one venous sample analyzed at our core laboratory (consid-
ered the standard measure). Agreement was achieved when the POC and lab INR 
values led to the same clinical decision. Differences in agreement between the POC 
devices and laboratory were assessed by McNemar’s test. In the current study, we 
applied the Bland-Altman method to determine if inferences regarding agreement 
between the POCs and laboratory were identical to the previous experiment where 
clinical decisions deﬁned agreement. RESULTS: The Avosure device was signiﬁcantly 
more likely to lead to the same clinical decision as the laboratory versus the ProTime 
device (80% vs. 66%, respectively, p < 0.001). However, the Bland-Altman method 
produced virtually identical mean bias (0.4 and 0.5 INR units, respectively) and did 
not distinguish between the devices. Statistical analysis of the Bland-Altman method 
produced the same ﬁndings for each device: signiﬁcantly different standard deviations 
between the POC and the laboratory (p < 0.001), signiﬁcant bias in each device (p < 
0.001), and high correlations between the POCs and the laboratory (0.925 and 0.926, 
respectively). CONCLUSIONS: The Bland-Altman method did not detect clinically 
important differences between the POC INR devices. Clinically meaningful agreement 
between measures of INR is optimally assessed by a method that directly observes or 
explicitly estimates clinical decisions.
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USING DIFFERENT MEASURES TO DETERMINE TIME IN THERAPEUTIC 
INR RANGE AMONG WARFARIN-TREATED PATIENTS FOLLOWING 
TOTAL HIP OR KNEE REPLACEMENT
Nordstrom B1, Kachroo S1, Nutescu E2, Schein J3, Fisher A3, Bookhart B3
1United BioSource Corporation, Lexington, MA, USA, 2The University of Illinois at Chicago, 
Chicago, IL, USA, 3Ortho-McNeil Janssen Scientiﬁc Affairs, LLC, Raritan, NJ, USA
OBJECTIVES: To determine the proportion of the post-surgery prophylaxis period 
that warfarin-treated patients undergoing total hip or total knee replacement (THR/
TKR) spent in the American College of Chest Physicians (ACCP)-recommended thera-
peutic international normalized ratio (INR) range using two methods: within-patient 
proportion and Rosendaal linear interpolation. METHODS: Using an electronic data-
base, patients undergoing total THR/TKR between January 1, 2004 and January 31, 
2009 who received warfarin within 3 days after surgery were identiﬁed and followed 
for up to 90 days. Analysis focused on Day 5 onward¯since warfarin takes several 
days to reach therapeutic effect¯and on patients with at least 2 measured INR levels 
during this period. INR results were categorized based on ACCP guidelines: in range 
(2–3), below range (<2), or above range (>3). The proportion of INR levels within 
each range was determined for each patient, and the distribution of these within-
patient proportions computed. Time within each range was imputed using the Rosend-
aal method, which assumes a linear interpolation between observed measurements, 
applying an INR level to each treatment day. RESULTS: A total of 653 THR and 871 
TKR patients were identiﬁed; both groups had a median of 5 INR measurements from 
Day 5. Median within-patient percentages of in-range INR values were 33% for the 
average THR patient and 29% for the average TKR patient. Using the Rosendaal 
method, THR patients spent a median 29% and TKR patients a median 28% of 
within-patient proportion of time within the INR 2–3 range. CONCLUSIONS: The 
within-patient proportion of actual INR values and the proportion of imputed days 
spent in the ACCP-recommended therapeutic range (2–3) were similar in this post-
surgical cohort of THR/TKR patients. Regardless of the method, the majority of INR 
values among all patients were outside of the ACCP-recommended INR therapeutic 
range.
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LINKING CLAIMS AND ELECTRONIC MEDICAL RECORD (EMR) DATA 
FOR A HYPERTENSION STUDY
Danielson E1, Chang S2, Long S3
1GE Healthcare, Hillsboro, OR, USA, 2Thomson Reuters, Washington, DC, USA, 3Thomson 
Reuters, Hampden, ME, USA
OBJECTIVES: To develop a methodology to link patients from two de-identiﬁed 
databases and leverage unique data from both to measure the impact of blood pressure 
and clinical ﬁndings on total costs. METHODS: Hypertensive patients (ICD-9 diag-
nosis 401.xx-405.xx) were identiﬁed from the MarketScan Commercial and Medicare 
Supplemental administrative claims databases (MarketScan) and the GE Centricity 
Electronic Medical Record (EMR) database (Centricity) for the years 2004–2008. A 
hybrid approach of deterministic and probabilistic matches was developed to identify 
common patients. Patients were included if they matched on zip code, gender and 
month of birth, and had at least three matching ofﬁce visit dates at a rate of 75% or 
higher. Patients were followed for 12 months after the initial diagnosis. MarketScan 
provided data on enrollment, all reimbursed services (medical and drug) and costs, 
and Centricity provided clinical and biometric details, such as body mass index (BMI) 
and blood pressure. RESULTS: Among the 3 million MarketScan and 1.5 million 
Centricity patients with hypertension, 31,786 met the matching criteria. Mean age 
was 58 and 54% were female. The demographic and clinical characteristics of these 
patients did not vary substantially from those of the two data sources. Among the 
31,786 patients, 84% received drug treatment, 56% had a BMI over 30 and mean 
systolic and diastolic values were 134 and 81, respectively. Mean unadjusted costs 
were $9,338 for patients with consistently controlled (ﬁrst and last systolic <140 and 
diastolic < 90) hypertension and $8,773 for patients not consistently controlled. 
CONCLUSIONS: A combined probabilistic and deterministic approach of linking 
patients yielded a sample size large enough to conduct a study and leverage the 
strengths of administrative and EMR data. Initial ﬁndings suggest that controlled 
patients incur higher costs, however, adjustments have not been made for additional 
demographic, clinical, and treatment characteristics.
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MODELING TRANSFORMED HEALTH CARE COSTS WITH UNKNOWN 
HETEROSKEDASTICITY
Baser O1, Yuce H2
1STATinMED Research / University of Michigan, Ann Arbor, MI, USA, 2STATinMED 
Research / City University of New York, Ann Arbor, MI, USA
OBJECTIVES: Log models are widely used to deal with skewed outcomes, such as 
health care costs. They improve precision of estimates and diminish the inﬂuence of 
outliers. Smearing estimation suggested in literature only works with homoskedastic 
or heteroskedastic errors due to categorical variables. Generalized linear models 
(GLM) have been proposed as an alternative to deal with any kind of heteroskedastic-
ity but recent literature shows that log models are superior to GLM under certain 
conditions. We present a method using log transformation that accounts for any kind 
of heteroskedasticity in the estimation of health care cost METHODS: Assume there 
is a population represented by the random vector of explanatory variables (ex. patient 
and clinical characteristics) and with the scalar response variable (ex. health care costs) 
and we want to estimate unknown parameters. Assume that error terms are in function 
of explanatory variables, and therefore heteroskedasticity exists. By modeling hetero-
skedasticity separately, we created a weight function and using this weight in an 
outcomes model, we corrected the heteroskedasticity in the log transformed model. 
Retransformation was done by adjusting for heteroskedasticity. RESULTS: As a case 
study, we calculated the burden of illness of venous thromboembolism (VTE). The 
difference between the cost of VTE and non-VTE patients is estimated to be $6,345 
and $8,239 depending on whether the proposed or a GLM model is used. The stan-
dard errors changed signiﬁcantly depending on the model. The difference was signiﬁ-
cant with the log transformed model with heteroskedasticity-adjusted standard errors 
and the GLM model. However, the difference was insigniﬁcant when the adjustment 
was not done. CONCLUSIONS: Log transformation provides more efﬁcient estima-
tors than GLM models under certain conditions (ex. if there is excess kurtosis) and 
heteroskedasticity can be adjusted even if its form is unknown.
PCV157
ACCOUNTING FOR TRIAL-EXCLUDED MEDICAL CONDITIONS WHEN 
SIMULATING MORTALTIY IN CLINICAL TRIAL POPULATIONS
Smolen H, Klein R, Myers J
Medical Decision Modeling Inc., Indianapolis, IN, USA
BACKGROUND: Clinical trials frequently exclude patients likely to die within the 
trial timeframe. Thus, these highly-selected patients have lower initial mortality prob-
abilities relative to the age- and gender-matched general population. OBJECTIVES: 
To capture the effect that clinical trial exclusion criteria have on intermediate-term 
(i.e., one- to ﬁve-year) death probabilities in study subjects with substantial asymp-
tomatic carotid artery stenosis. METHODS: We “phased-in” certain relevant death 
probabilities in a microsimulation model using data from the Asymptomatic Carotid 
Atherosclerosis Study (ACAS). The phase-in process initially eliminates or greatly 
reduces the mortality probability from a condition (reﬂecting patients excluded with 
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that condition) and increases the mortality probability as time progresses (reﬂecting 
patients that entered the trial with less severe and undetected cases of the condition 
or who developed the condition during the trial). Mortality was phased-in for four 
conditions reﬂective of their high prevalence and consistency with exclusion criteria: 
CHD, malignant neoplasms, chronic lower respiratory disease, and liver disease. 
RESULTS: To statistically compare the ACAS simulated versus actual mortality sur-
vival curves, we calculated the absolute differences between the curves and performed 
a standard equality of probabilities test on the curves at 12, 24, 36, 48, and 60 months. 
For the ACAS curve without mortality phase-in, at all times t before 60 months the 
simulated and actual curves had a statistically signiﬁcant difference (0 < p < 0.04). 
With mortality phase-in, there was no evidence at any time t that the simulated and 
actual curves had a statistically signiﬁcant difference (0.62 < p < 0.95). CONCLU-
SIONS: Phasing in mortality probabilities for trial-excluded conditions can simulate 
mortality survival curves that reﬂect the control arms of clinical trials.
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RARE EVENT BIAS IN RETROSPECTIVE ANALYSIS OF  
OUTCOMES MEASURES
Baser O1, Yuce H2, Wang L3
1STATinMED Research / University of Michigan, Ann Arbor, MI, USA, 2STATinMED 
Research / City University of New York, Ann Arbor, MI, USA, 3STATinMED Research, Ann 
Arbor, MI, USA
OBJECTIVES: It is well documented that standard logit regressions are biased in rare 
events. We wanted to illustrate how to analyze rare events in observational analysis 
using Medicare claims data. In particular, we compared the operational mortality for 
patients who underwent hip fracture surgery and suffered venous thromboembolism 
(VTE). METHODS: We applied two correction methods to address possible rare event 
bias. The ﬁrst method involved obtaining information about the fraction of those in 
the population and the observed fraction of those in the sample. We estimated the 
adjusted constant coefﬁcient in the logit model. In the second method, we weighted 
the proportion of ones and zeros in the sample to equal the true proportion in the 
population. We tested for differences in predicted probabilities using a non-parametric 
test. The Mann-Whitney U test and Kolmogorov-Smirnov two sample test can both 
be used on predicted probabilities of logit regression to see whether differences exist. 
RESULTS: To apply the methodology, we constructed a retrospective cohort study 
comparing the operational death rate between patients who underwent hip replace-
ment surgery who suffered VTE and patients who did not suffer VTE. 60,245 patients 
with hip fracture surgery were identiﬁed from the 100% Medicare Inpatient dataset. 
Mortality was rare (0.81% vs. 3.34% for patients with non-VTE vs. VTE). Using 
Monte Carlo simulation, the unadjusted rate was 0.97% for non-VTE patients and 
4.36% for VTE patients. The odds ratio was 3.98 for the standard model, 3.98 for 
the prior correction method, and 4.37 for the weighted mechanism. The predicted 
event probabilities were signiﬁcantly different. CONCLUSIONS: Standard logit 
regression is proven to underestimate probabilities with rare events. We examined two 
correction methods. The predicted event probabilities adjusted for rare event bias were 
signiﬁcantly different from the unadjusted ones.
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COMPARATIVE EFFECTIVENESS INDEX: A CONCEPTUAL APPROACH 
TO COMPARATIVE EFFECTIVENESS RESEARCH
Hagan M1, Lee EH2, Arikian S3, Pizzi LT2
1Daiichi Sankyo, Inc., Parsippany, NJ, USA, 2Thomas Jefferson University, Philadelphia, PA, 
USA, 3Genesis BioPharma Group, New York, NY, USA
OBJECTIVES: The Comparative Effectiveness Index (CEI) provides a quantitative 
method of transforming efﬁcacy data into effectiveness indices. In lieu of head-to-head 
randomized controlled trials, the CEI uses efﬁcacy, adherence, and safety data to 
facilitate the drug evaluation process by providing a single value index for each thera-
peutic alternative. METHODS: Efﬁcacy data from clinical trials serve as surrogate 
markers of effectiveness. In analyzing two hypothetical anti-hypertensive drugs, A and 
B, the efﬁcacy of each drug is ranked on a nominal scale based on the literature: A = 
10 and B = 8. The drug with the highest nominal value is the most efﬁcacious. 
However, this value needs to be moderated by adherence and safety data. Adherence 
rates, calculated from claims databases for example, are: A = 60% and B = 90%. The 
formula for calculating the Modiﬁed Efﬁcacy Score (MES) of each drug is the (adher-
ence rate*efﬁcacy score)/100: A = 6 and B = 7.2. Adverse events (AE) reported in the 
clinical trials are ranked based on severity, the scale is anchored at 0 and 100 where 
0 = No AE and 100 = Death. Each AE is assigned a value depending on its severity 
then multiplied by the probability of its incidence. This is repeated for each AE and 
summed. The inverse of the sum, the Adverse Events Score (AES), is used in the ﬁnal 
computation so that both MES and AES modiﬁers have a direct relationship with the 
CEI. The AES for the drugs are: A = 3.33 and B = 5.00. The MES is multiplied by the 
AES to calculate the CEI. Consequently, the CEI would be: A = 19.98 and B = 36.00. 
Although drug A was more efﬁcacious, drug B is more effective. CONCLUSIONS: 
The CEI provides health care decision-makers with valuable comparisons between 
therapeutic alternatives, but it requires further development and validation. Incorpo-
rating measures of dispersion for efﬁcacy and compliance in a sensitivity analysis can 
generate more comprehensive indices.
INDIVIDUAL’S HEALTH – Clinical Outcomes Studies
PIH1
THE NATIONAL BURDEN OF PEDIATRIC ADVERSE DRUG EVENTS: A 
CASE-CONTROL STUDY USING THE 2006 KIDS’ INPATIENT DATABASE
Tundia N, Heaton PC, Kelton CM
University of Cincinnati, Cincinnati, OH, USA
OBJECTIVES: Pediatric adverse drug events (ADEs) lead to substantial burden on 
patients, caregivers, and payers. The objective of the current study was to quantify 
the extent of the national pediatric ADE burden by determining (1 the frequency of 
ADE occurrence; (2 excess length of stay (LOS) and excess cost associated with 
hospitalization; and (3 the hospital, patient, and ADE characteristics that predict 
excess LOS and excess cost. METHODS: Using the 2006 Kids’ Inpatient Database, 
ADEs were identiﬁed using ICD-9 and supplemental Ecodes; ADE frequencies were 
computed. A hospitalization with an ADE was matched with 1 hospital visit without 
an ADE; matching criteria included the All Patient Reﬁned-Diagnosis Related Group, 
which accounts for severity of illness and risk of mortality, and gender and age. Excess 
LOS and excess cost (totals and means) were calculated for case-control pairs. An 
ordinary-least-squares regression was run, with the case-control pairs as observations, 
to determine signiﬁcant predictors of excess LOS and excess cost. RESULTS: In 2006, 
118,779 ADEs occurred in 99,320 visits out of 7,558,812 total pediatric hospitaliza-
tions. The mean excess LOS was 0.98 days (p < 0.0001), while the mean excess cost 
was $2,252 (p < 0.0001). Adverse effects from benzodiazepine-based tranquilizers, 
certain anticonvulsants, adrenal corticosteroids, and various antibiotics led to the 
highest excesses (all with p < 0.0001). The mean excess LOS and excess cost, respec-
tively, for neonates aged 0–7 days were 6.4 days (p < 0.0001) and $26,417 (p < 
0.0001). Statistically signiﬁcant predictors included age, hospital region, insurance 
coverage, hospital size, urban versus rural hospital location, major diagnostic category 
for hospital admission, and severity of illness. CONCLUSIONS: A substantial share 
of the pediatric ADE burden is accounted by adverse effects rather than accidental 
poisoning. Variation across regions, drug classes, and diagnoses suggests that efforts 
to reduce the ADE burden can be targeted to have the greatest impact.
PIH2
THE PREVALENCE AND USE OF POTENTIALLY INAPPROPRIATE 
MEDICATION IN ELDERLY POPULATION USING NATIONAL NURSING 
HOME SURVEY
Surbhi S
St John’s University, jamaica, NY, USA
OBJECTIVES: The aim of the study is to determine the prevalence and use of poten-
tially inappropriate medication in elderly population according to the Beer’s criteria. 
METHODS: Data for the present study was obtained from National Nursing Home 
Survey (NNHS) 2004. Patients of the age 65 and above were taken as sample. The 
use of potentially inappropriate medication was assessed by ranking the rate of usage 
of the 48 medications listed in the Beer’s criteria that should be avoided in elderly 
patients and assessing the medication usage across demographics like gender and age. 
Descriptive statistics were carried out using SPSS 17. RESULTS: The total number of 
cases of the age 65 and above using the potentially inappropriate medication was 
2209. The top ﬁve most used drugs were ferrous sulfate ( 54.33%), Clonidine ( 7.8%), 
Lorazepam ( 6.9%), Biscodyl ( 6.9%) and Amioderone (5.7%). Other more used drugs 
were Nifedipine ( 2.6%), Amitryptyline ( 2.5%), Alprazolam (2.2%), Fluoxetine ( 
1.6%), Naprozen ( 1.4%), Temezepam (1.1%), Diazepam ( 0.95%) and Nitrofuroin-
toin (0.90%). The usage was more in female (73.7%) as compared to male (26.3%), 
it was more in the age group 85 to 100 ( 43.1%) compared to 65 to 74 ( 17.9%) and 
75 to 84 ( 39.1%). There were 2208 (91.8%) elders using at least one of the 48 medi-
cations and 181( 8.1%) elders using two of these 48 medications. CONCLUSIONS: 
The use of potentially inappropriate medication listed under Beer’s criteria is highly 
prevalent among the elderly. There is more usage in females compared to males and 
more in the age group 85 to 100. Among the top 12 drugs used, accept for Ferrous 
sulfate and Clonidine which has the low Beer’s severity rating, all other drugs have a 
high Beer’s severity rating and causes Adverse Drug Events.
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RISK OF WEIGHT GAIN WITH THE USE OF SELECTIVE SEROTONIN 
REUPTAKE INHIBITORS (SSRI) AND ATYPICAL ANTIPSYCHOTICS 
(SGA) COMBINATION TREATMENT IN CHILDREN AND ADOLESCENTS
Bhowmik D1, Chen H1, Aparasu RR1, Bhatara V2
1University of Houston, Houston, TX, USA, 2University of South Dakota, Sioux Falls, 
SD, USA
OBJECTIVES: To estimate the risks of gaining weight, with the use of selective 
serotonin reuptake inhibitors (SSRI) and atypical antipsychotics (SGA) in combination 
among children and adolescents. METHODS: A retrospective cohort study was con-
ducted using 2003–2005 Medicaid Analytic eXtract (MAX) data from four U.S. states. 
Combination pharmacotherapy was operationalized as the concurrent prescribing of 
SSRI and SGA, where at least 14 days of treatment overlap occurred. Long term 
combination use is deﬁned as an overlap beyond 60 days. Children and adolescents 
aged 6–18 years, and enrolled in Medicaid during 3 months prior and 1 year post the 
treatment initiation were selected. Multivariable logistic regression models were 
employed to estimate the risks of gaining weight during the one year follow up period. 
RESULTS: Among 118,126 children and adolescents received SSRI or SGA, 
56,091(12.5%) were on combination treatment and of which approximately 80% 
were on long-term therapy (>60 days). Vast majority (63%) of these recipients were 
